Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
about
Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer's diseaseA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkersSuspected non-Alzheimer disease pathophysiology--concept and controversyFacilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich ImmunoassaysFluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsPro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's DiseaseAutosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical ADBiological markers of Alzheimer's diseaseHarmonized diagnostic criteria for Alzheimer's disease: recommendationsMild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's diseaseHarnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and ChallengesEmerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applicationsPersonalized health care beyond oncology: new indications for immunoassay-based companion diagnosticsThe corticobasal syndrome-Alzheimer's disease conundrumIndividual subject classification of mixed dementia from pure subcortical vascular dementia based on subcortical shape analysisHigh Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal FluidTaurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's diseaseCSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's diseaseTracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersNeurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive DimensionsDkk-3 is elevated in CSF and plasma of Alzheimer's disease patientsPittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer diseaseThe Mental Status Examination in Patients With Suspected Dementia.Neuropsychological Testing and Machine Learning Distinguish Alzheimer's Disease from Other Causes for Cognitive Impairment.Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration.Multimodal techniques for diagnosis and prognosis of Alzheimer's diseasePreoperative cerebrospinal fluid β-Amyloid/Tau ratio and postoperative delirium.Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.Cerebrospinal fluid biomarkers of Alzheimer's disease.Diagnosis and biomarkers of predementia in Alzheimer's disease.Latent feature representation with stacked auto-encoder for AD/MCI diagnosisNovel CSF biomarkers for Alzheimer's disease and mild cognitive impairmentEffect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer diseaseAnxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment.Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.Integrating ADNI results into Alzheimer's disease drug development programs.Serial MRI and CSF biomarkers in normal aging, MCI, and ADLessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
P2860
Q21129438-1467EE01-9F1E-4764-B6B5-F183BBC3CFF3Q26745508-6D685D79-2C1A-47A8-B98A-270E008C982CQ26771270-4DA4F6DA-9AA4-4B6B-B6F7-280566450FFDQ26781562-87911B16-7B2D-4F47-AB4B-98AE3C65D41EQ26784569-B325C5EC-89A0-4638-928A-5855C164BF59Q26795492-089DDAAD-DA82-4D77-82EA-0269E1D01D67Q26801666-0C6A44CF-98FF-46EB-9D9F-F20B434DBA4CQ26823847-0F127C65-547B-4F7F-99E7-295928D03E4AQ27009157-E61658B8-94AC-4A32-B0D0-A8B4E684441AQ27027319-B82C2430-C25C-48AF-967D-10FFD4FF69EBQ28072061-2F426AAF-25D1-46BC-AD26-5461E581290BQ28081849-59EDAEAA-D9C0-4A38-A6BD-F25066F6547CQ28084590-495E3819-526F-4ACD-918C-F12CB84830B1Q28250881-B2DA940B-55BF-47A3-AB2C-15A60FE48176Q28534320-A93EF4BA-B8AE-41FC-BF9E-6BB269665721Q28547231-69F0FBA1-7B02-498C-863E-72BFAA89C8D6Q28649926-0750065B-30F5-4572-AC33-65F1D6D76BBAQ28728773-F4DE68EF-6D21-4A41-A43B-00D2AE06EF4EQ29620245-04D254E1-9570-4F1F-A1C2-857399448BADQ30998279-F56051C5-BC83-4204-9D35-0B561071AFEDQ33448926-75F2B7E5-E0C4-49E1-AFF8-8148760F958FQ33560183-6E0F1986-3BA1-408A-A2D2-2D97F401DC7DQ33562433-880F55A4-4DAE-49FD-B4AE-693E36C704A7Q33599831-80EC7261-1314-42BA-A876-DF3CEACC22E2Q33603263-45338117-CF85-45FE-A6E3-E0104A79FED1Q33607535-C4ABC254-E02E-4B01-9382-A9E7C86DCF58Q33644582-5914E7B0-D5E9-4274-B365-2CC1DB439878Q33687554-86431167-638F-48B9-8400-A6D90101F697Q33757828-93661209-2089-4C2D-BF35-CBC7CAC08419Q33777509-93AB1E06-2E8F-4313-AFA2-C201122B9117Q33787457-8B1CFC5F-96C4-4265-B402-FE1896815886Q33894316-8276ACF2-747E-452D-AEAF-C20137B91A0BQ33917722-6B3DE35F-18EA-432F-8DB2-ACBB5FEBD960Q33924292-90D4D88D-8133-43FE-AD1C-80B8FAF7D39BQ33924646-865FDBCD-833F-495B-BFDA-65A5C6B9D281Q33953180-10D05BC9-9521-4C03-BC81-8CC32BF276A1Q33987409-20AABC93-7F36-4E8D-9E2F-810C2AFD4E3DQ34002953-B3C6986D-BD62-467D-9146-97A1932B4409Q34043074-0B5CBC24-2055-410E-A08A-4931BD8ACF3BQ34247849-4B41AD68-FD7A-4F1D-BBC7-B7ED598EAA0C
P2860
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Cerebrospinal fluid {beta}-amy ...... thologic changes in the brain.
@en
Cerebrospinal fluid {beta}-amy ...... thologic changes in the brain.
@nl
type
label
Cerebrospinal fluid {beta}-amy ...... thologic changes in the brain.
@en
Cerebrospinal fluid {beta}-amy ...... thologic changes in the brain.
@nl
prefLabel
Cerebrospinal fluid {beta}-amy ...... thologic changes in the brain.
@en
Cerebrospinal fluid {beta}-amy ...... thologic changes in the brain.
@nl
P2093
P921
P1433
P1476
Cerebrospinal fluid {beta}-amy ...... thologic changes in the brain.
@en
P2093
Irina Alafuzoff
Laura Parkkinen
Päivi Hartikainen
Tero Tapiola
Tuula Pirttilä
P304
P356
10.1001/ARCHNEUROL.2008.596
P577
2009-03-01T00:00:00Z